Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy

Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation)

“…No radiotherapy was delivered before TSEBT. These data were collected to evaluate their impact on response rates (15).…”

Mycosis Fungoides

“…The complete response of only 10 (55.6%) of the 18 patients to total skin electron beam irradiation at initial therapy may be explained by the fact that 4 of 18 patients had stage III disease, and 8 of the 14 remaining patients had MF-associated follicular mucinosis, a combination known to be rather refractory to total skin electron beam irradiation. 25 The disease-related and overall survival for the whole group of 309 patients was 89% and 80% at 5 years, and 75% and 57% at 10 years, respectively. For the survival rates for the different stages of MF, the overall and disease-specific survival rates at 5 and 10 years for patients with stage Ia and Ib MF (Table 2) were similar to those reported in previous studies.…”

Apoptosis and Cutaneous T Cell Lymphoma

“…Of note, however, is the exquisite sensitivity of neoplastic T cells, even in advanced disease, to the rather small daily fractions (100 cGy or less) that can be employed with good therapeutic effect. Such small daily doses are relatively ineffective inducers of apoptosis in cells other than lymphocytes (e.g., keratinocytes, endothelial cells, fibroblasts) and explain the favorable therapeutic results and low short‐ and long‐term toxicities one obtains with protracted fractionation regimens (100 cGy/day, 4 days wk/9 wks) such as the Yale regimen employed for total skin electron beam radiation therapy (TSEBT) 29…”